Clinical trials: Thorough QT/QTc Study
Effects of Sativex on ECG
Sativex Thorough QT/QTc Study
This study was to evaluate effects of Sativex on electrocardiogram (ECG) traces when administered at its therapeutic dose of 8 sprays per day and at multiples of the therapeutic dose (24 or 36 sprays per day), and to evaluate its…
- Trial name
- NCT01322139
- Where
- Canada
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- Jazz Pharmaceuticals
Myelofibrosis
QT Interval/Corrected QT Interval （QT/QTc） Clinical Study to Evaluate the Cardiac Safety of TQ05105 Tablets in Healthy Participants
Primary Objective: To evaluate the effect of single-dose TQ05105 on QTcF interval in healthy Chinese participants. Secondary Objectives: To evaluate the effects of single-dose TQ05105 on other cardiac parameters (heart rate, QT…
- Trial name
- NCT07708272
- Testing
- TQ05105 tablets, Moxifloxacin Hydrochloride Tablets
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Fibromyalgia
Phase 1 Thorough QT (TQT) Study in Young Healthy Volunteers
This Phase 1 study will assess the effects of esreboxetine on the heart. In particular the effects on a specific electrocardiogram (ECG) measurement called QTc will be measured.
- Trial name
- TQT (NCT00809289)
- Testing
- esreboxetine, moxifloxacin
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
ANX-188 Thorough QT/QTc Study in Healthy Volunteers
This study has been designed in compliance with the ICH-E14 guideline (2005) to evaluate the effect of ANX-188 at therapeutic and supratherapeutic concentrations on cardiac repolarization, specifically, Fridericia's QT-Interval…
- Trial name
- NCT01790087
- Testing
- ANX-188 Therapeutic Dose, ANX-188 Supratherapeutic dose, Saline
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Mast Therapeutics, Inc.
Healthy Volunteers
A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements
The main aim of this study is to find out how more than one dose of TAK-279 changes the heart-rate corrected QT (QTc) interval of healthy adults.
- Trial name
- NCT06258265
- Testing
- TAK-279, Moxifloxacin
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Takeda
Cardiotoxicity
Staccato Prochlorperazine Thorough QT/QTc
To assess the safety of Staccato Prochlorperazine on cardiac repolarization (QTc interval duration) at 2 dose levels compared to placebo in healthy volunteers.
- Trial name
- NCT00543062
- Testing
- Inhaled prochlorperazine 5 mg, Inhaled prochlorperazine 10 mg, Oral moxifloxacin
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Alexza Pharmaceuticals, Inc.
Cardiac Repolarization in Healthy Subjects
A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects
The purpose of this trial is to assess the effects of a single supratherapeutic dose of carbidopa on cardiac repolarization relative to placebo in healthy adult subjects.
- Trial name
- NCT06161220
- Testing
- Carbidopa capsule, Moxifloxacin Tablets, USP
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Impax Laboratories, LLC
Healthy Volunteers
Thorough QT Assessment of Cedazuridine in Healthy Subjects
This study is designed to evaluate the effect of therapeutic and supratherapeutic oral doses of cedazuridine on cardiac repolarization, as detected by QTc in healthy subjects, in accordance with regulatory guidelines.
- Trial name
- NCT04953923
- Testing
- Cedazuridine, Moxifloxacin
- Where
- Netherlands
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Astex Pharmaceuticals, Inc.
Cardiac Conduction and Repolarization
Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization
This is a 3-arm, parallel-group, active- and placebo-controlled, double-blind, randomized study, to compare treatment with intravenous custirsen at 640 mg (highest intended therapeutic dose) with placebo.
- Trial name
- NCT01874561
- Testing
- Custirsen, Moxifloxacin
- Where
- United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Achieve Life Sciences
Healthy Volunteers
Cardiac Safety Evaluation of P03277
The study is a Phase I, Single center, Randomized, Cross-over Double-blind Placebo-controlled and Open-label Positive-controlled (moxifloxacin) in healthy volunteers.
- Trial name
- NCT03657264
- Testing
- P03277 0.1 mmol/kg, Moxifloxacin 400mg, NaCl 0.9%
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Guerbet
Healthy
A TQT Study of Effect of M2951 on Cardiac Repolarization
The purpose of this study is to assess potential effects of M2951 on cardiac repolarization (i.e. prolongation of QT interval).
- Trial name
- NCT07214935
- Testing
- Moxifloxacin, M2951 Low Dose, M2951 High Dose
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
QT Intervals Changes, QTc Intervals Changes
Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults
The primary objective of this study is to assess the effect of a single therapeutic (50 mg) oral dose of omecamtiv mecarbil (OM) on the QT interval / QT interval corrected for heart rate (QTc), relative to placebo, in healthy…
- Trial name
- NCT04175808
- Testing
- Omecamtiv Mecarbil (OM), Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Cytokinetics
Healthy
CP-690,550 Thorough QTc Study
ICH E14 recommends that a thorough QT/QTc (TQT) study should be performed to determine whether intensive monitoring of QT interval in target patient populations is required during later stages of development.
- Trial name
- NCT01743677
- Testing
- CP-690,550, Moxifloxacin
- Where
- 2 sites in Belgium, Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers
The purpose of the study is to evaluate the effect of Nestorone (NES) administered as an bolus injection on the corrected QT interval using Fridericia's formula (QTcF).
- Trial name
- NCT02236026
- Testing
- Supratherapuetic dose of Nestorone, Moxifloxacin
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Population Council
Abnormalities, Cardiovascular
A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers
The primary objective of this study is to assess the corrected QT interval (QTc) effect of volanesorsen (ISIS 304801) administered as a 300 mg subcutaneous (SC) therapeutic and a 300 mg intravenous (IV; 2-hour infusion)…
- Trial name
- NCT02910635
- Testing
- Volanesorsen, Moxifloxacin
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Healthy Participants
A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants
This study will assess the effect of single oral doses of baxdrostat on the ECG interval measured from the onset of the QRS complex to the end of the T wave (QT) interval corrected for HR using Fridericia's formula (QTcF)…
- Trial name
- NCT06194032
- Testing
- Baxdrostat, Moxifloxacin
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects
The Phase I Thorough QT/QTc (TQT) study will be performed in a single center, the Vince \& Associates Clinical Research, Inc., clinical trials unit (CTU), in 72 healthy male or female subjects, aged 18 to 45 years inclusive, to…
- Trial name
- NCT03613649
- Testing
- AZD0914, Moxifloxacin
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cystic Fibrosis
An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants
The purpose of this study is to evaluate the effect of Vanzacaftor (VNZ) on QTcF, as well as the pharmacokinetic (PK), safety, and tolerability of VNZ in healthy participants.
- Trial name
- NCT05867147
- Testing
- Vanzacaftor, Moxifloxacin
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Healthy
CAEB071 Thorough QTc Study in Healthy Volunteers
This study has been designed in compliance with the ICH-E14 guideline 2005 to evaluate the QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs.
- Trial name
- NCT01594255
- Testing
- sotrastaurin, Avelox
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Constipation
Thorough Corrected QT Interval (QTc) Study To Evaluate Possible Effects of Prucalopride on ECG Parameters
This is a 2-arm, parallel-group active- and placebo-controlled, double-blind randomised study, stratified by gender and with a hybrid crossover group design, to compare treatment with prucalopride 2 mg/day (intended therapeutic…
- Trial name
- NCT00903747
- Testing
- prucalopride, moxifloxacin
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Movetis